EBRO 2017

GEC-ESTRO APBI trial: Patient characteristics

1328 randomised from 2004 to 2009

Median age 62; Median follow-up 6.6 years

95% invasive carcinoma; 86% pT1

APBI n = 633: 119 PDR 451 HDR 8# 59 HDR 7#

90% G1-G2 75% ductal NST 92% ER+

87% adjuvant endocrine therapy 11% chemotherapy

Strnad V et al (2016) Lancet 387:229-238

Courtesy Chris Cottrill